Biomolecular Characterization Device
RedShift BioAnalytics Inc.Request Info
BURLINGTON, Mass., May 17, 2022 — 
The Apollo biomolecular characterization device from RedShift BioAnalytics Inc. uses microfluidic modulation spectroscopy (MMS) technology to provide sensitive, precise measurements of biomolecule structures.
Users are able to compare higher-order structure and similarity profiles for confidence in structural similarity and activity to inform discovery, screening, formulation, and quality control in biopharmaceutical drug development. The device provides accurate and reproducible measurements with a broad concentration range from 0.1 mg/ml to >200 mg/ml, allowing measurement in native conditions.
https://www.redshiftbio.com
/Buyers_Guide/RedShift_BioAnalytics_Inc/c12636
Published: May 2022
REQUEST INFO ABOUT THIS PRODUCT
* First Name:
* Last Name:
* Email Address:
* Company:
* Country:
Message:
When you click "Send Request", we will record and send your personal contact information to RedShift BioAnalytics Inc. by email so they may respond directly. You also agree that Photonics Media may contact you with information related to this inquiry, and that you have read and accept our
Privacy Policy and
Terms and Conditions of Use.
Register or login to auto-populate this form:
Login
Register
* Required